Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 83-89

  Fischetti, F ^a   Candido, R ^b   Toffoli, B ^a   Durigutto, P ^a   Bernardi, S ^a   Carretta, R ^a   Tedesco, F ^a   Fabris, B ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Blood Transfusion Center   (Italy)

Author keywords

Atherosclerosis; Diabetes mellitus; Inflammation; Innate immunity; Leukocytes trafficking; Rat; Terminal complement complex

Indexed keywords

CELL ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PROLIFERATIVE CELL NUCLEAR ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INNATE IMMUNITY; LEUKOCYTE; MALE; MESENTERIC ARTERY; METABOLIC PARAMETERS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; VASCULITIS;

ANALYSIS OF VARIANCE; ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C6; COMPLEMENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HYPERTROPHY; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTE ROLLING; MALE; MESENTERIC ARTERIES; MICROSCOPY, VIDEO; PLATELET-DERIVED GROWTH FACTOR; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, TRANSGENIC; RATS, WISTAR; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79955533950     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.050     Document Type: Article

References (30)

1. Garcia M.J., McNamara P.M., Gordon T., Kannel W.B. Morbidity and mortality in diabetics in the Framingham population Sixteen year follow-up study. Diabetes 1974, 23:105-111.
2. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
3. Uesugi N., Sakata N., Nangaku M., et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am J Kidney Dis 2004, 44:224-238.
4. Hodgkinson C.P., Laxton R.C., Patel K., Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:2275-2281.
5. Fischetti F., Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006, 39:417-428.
6. Tedesco F., Bulla R., Fischetti F. Terminal complement complex: regulation of formation and pathophysiological functions. The complement system: novel roles in health and disease 2004, Kluwer Academics, Boston, p. 97-127.
7. Busche M.N., Walsh M.C., McMullen M.E., Guikema B.J., Stahl G.L. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 2008, 51:1544-1551.
8. La Bonte L.R., Davis-Gorman G., Stahl G.L., McDonagh P.F. Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2008, 294:H1282-H1290.
9. Jerath R.S., Burek C.L., Hoffman W.H., Passmore G.G. Complement activation in diabetic ketoacidosis and its treatment. Clin Immunol 2005, 116:11-17.
10. Vasil K.E., Magro C.M. Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. J Am Acad Dermatol 2007, 56:96-104.
11. Zhang J., Gerhardinger C., Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002, 51:3499-3504.
12. Seifert P.S., Hugo F., Hansson G.K., Bhakdi S. Prelesional complement activation in experimental atherosclerosis Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989, 60:747-754.
13. Bhakdi S., Dorweiler B., Kirchmann R., et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995, 182:1959-1971.
14. Paul A., Ko K.W., Li L., et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004, 109:647-655.
15. Oksjoki R., Jarva H., Kovanen P.T., Laine P., Meri S., Pentikainen M.O. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003, 23:630-636.
16. Niculescu F., Rus H.G., Vlaicu R. Immunohistochemical localization of C5b-9, S-protein C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987, 65:1-11.
17. Schmiedt W., Kinscherf R., Deigner H.P., et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998, 18:1790-1795.
18. Hamilton K.K., Sims P.J. The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells. J Clin Invest 1991, 88:1833-1840.
19. Lewis R.D., Jackson C.L., Morgan B.P., Hughes T.R. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol Immunol 2010, 47:1098-1105.
20. Cybulsky M.I., Iiyama K., Li H., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
21. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997, 185:1619-1627.
22. Benzaquen L.R., Nicholson-Weller A., Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994, 179:985-992.
23. Acosta J., Hettinga J., Fluckiger R., et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000, 97:5450-5455.
24. Altannavch T.S., Roubalova K., Kucera P., Andel M. Effect of high glucose concentrations on expression of ELAM-1 VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 2004, 53:77-82.
25. Kivisaari L. The effect of experimental pancreatitis and diabetes on the microvasculature of the rat pancreas. Scand J Gastroenterol 1979, 14:689-695.
26. Fabris B., Candido R., Armini L., et al. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. J Hypertens 1999, 17:1925-1931.
27. Candido R., Forbes J.M., Thomas M.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003, 92:785-792.
28. Liu Y., Liang C., Liu X., et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE MAPK and NF-kappaB pathways. Atherosclerosis 2009, 208:34-42.
29. Candido R., Jandeleit-Dahm K.A., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253.
30. Couser W.G., Nangaku M. Cellular and molecular biology of membranous nephropathy. J Nephrol 2006, 19:699-705.